Orthopedics firm ForCast enters alliance with KORU Medical Systems for a new antibiotic infusion treatment therapy
KORU Medical Systems and ForCast Orthopedics Partner for PJI Treatment
In a significant development for the medical industry, KORU Medical Systems and ForCast Orthopedics have announced a partnership to leverage KORU's FreedomEDGE infusion system for the treatment of periprosthetic joint infection (PJI).
Based in the United States, KORU Medical Systems is a company whose mission is to provide infusion technologies for various medical applications. Established in 1994, the Freedom Syringe Infusion System, their flagship product, received its first FDA clearance that year. KORU Medical develops, manufactures, and commercializes large volume subcutaneous infusion solutions, and their products are customizable for commercial use by biopharmaceutical companies during feasibility/clinical trials.
ForCast Orthopedics, on the other hand, is a development-stage company focused on the treatment of PJI with targeted antibiotic therapy. Their lead program, FC001, has received both Orphan Drug Designation and Qualified Infectious Disease Program (QIDP) designation from the US Food & Drug Administration. These designations enable eligibility for Fast-Track Designation and Priority Review.
Peter Noymer, Executive Chairman and CEO of ForCast, expressed his confidence in KORU's products, stating that they are best suited for partnering with ForCast's WIIS platform and meeting the needs of PJI patients. Linda Tharby, President and CEO of KORU Medical, echoed this sentiment, expressing excitement about working with ForCast to help them achieve their mission to modernize the standard of care for PJI.
The partnership anticipates initiating a clinical trial in 2026. KORU Medical's FreedomEDGE pump will support ForCast's proprietary delivery system, WIIS, for PJI treatment. The Freedom System includes Freedom60®, FreedomEDGE® Syringe Infusion Drivers, Precision Flow Rate Tubing^{TM}, and HigH-Flo Subcutaneous Safety Needle Sets^{TM}.
The success of KORU Medical's technology supporting ForCast's WIIS and the timing to complete the clinical readiness assessment are subject to risks and uncertainties. However, both companies are optimistic about the potential benefits this collaboration could bring to patients suffering from PJI.
For more information about KORU Medical Systems, please visit their website at www.korumedical.com. Investor contacts for KORU Medical are Peter Noymer ([email protected]) and Louisa Smith ([email protected]).
In addition to this partnership, KORU Medical's Pharma Services and Clinical Trials business supports drug development processes. The company is also collaborating with WhiteSwell and CLINIPACE for a clinical trial program to treat PJI, which is expected to begin in early 2026.
This partnership marks a significant step forward in the fight against PJI, a serious and often debilitating condition. By combining their expertise and technologies, KORU Medical Systems and ForCast Orthopedics aim to provide innovative solutions and improve the lives of patients worldwide.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
- Various forms of cataracts include nuclear, pediatric, traumatic, and additional types
